Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- April-June Generic Share at 49.8% under New Formula: JGA
October 29, 2014
- JPMA to Launch Compound Library Joint Purchasing Initiative; Full-Scale Purchasing to Begin in FY2015
October 29, 2014
- FPMAJ Sets Up Panel to Discuss Selective Sales Tax Breaks
October 27, 2014
- Japan CRO Association Nearing Remote Verification Agreement with Cancer Treatment Center
October 22, 2014
- JPMA Tones Down Demand on R&D Tax Credit System, Calls for “Maintenance” Instead of “Perpetuation”
October 20, 2014
- JMA Pres. Frets Proposed Introduction of Reference Pricing Rule
October 17, 2014
- JPMA Decides on More Close-Up Disclosure for R&D Outlays
October 17, 2014
- Industry Associations Call for Delay in Ratification of COP10 Nagoya Protocol
October 10, 2014
- US Nonprofit ACRES Launches Japan Branch
October 8, 2014
- National University Hospital Council’s Guidelines Not to Require Disclosure of Individuals’ Names
October 7, 2014
- JPMA Plans Disclosure of Recipients, Amount of Payments for R&D Outlays
October 3, 2014
- Bayer Yakuhin President to Become New EFPIA Japan Chairman
October 2, 2014
- JPMA Weighs Disclosure of Ad Payments to Commercial Medical Publishers
September 26, 2014
- JPMA to Unify Method of Disclosing Sensitive Payment Information from Next Year
September 22, 2014
- JPMA to Suspend Hasegawa’s Veep Activities for Another 6 Months over CASE-J
September 19, 2014
- CDISC CEO Advises Drug Makers to Collect Data Based on CDASH
August 27, 2014
- NEDO, NCC, Toray to Jointly Develop Simple Test Systems for Cancers and Dementia
August 20, 2014
- Fair Discussions Necessary for Full Introduction of New Drug Development Premium: Chuikyo Member
August 12, 2014
- Drug Price Settlement Rate Will Rise towards Sept.: JPWA Chief
August 11, 2014
- OTC Drug Federation Requests Ministry to Advance Prescription-to-OTC Switches
July 31, 2014
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…